36232909|t|The Interplay between GSK3beta and Tau Ser262 Phosphorylation during the Progression of Tau Pathology.
36232909|a|Tau hyperphosphorylation has been linked directly to the formation of toxic neurofibrillary tangles (NFTs) in tauopathies, however, prior to NFT formation, the sequence of pathological events involving tau phosphorylation remains unclear. Here, the effect of glycogen synthase kinase 3beta (GSK3beta) on tau pathology was examined independently for each step of transcellular propagation; namely, tau intracellular aggregation, release, cellular uptake and seeding activity. We find that overexpression of GSK3beta-induced phosphorylated 0N4R tau led to a higher level of tau oligomerization in SH-SY5Y neuroblastoma cells than wild type 0N4R, as determined by several orthogonal assays. Interestingly, the presence of GSK3beta also enhanced tau release. Further, we demonstrated that cells endocytosed more monomeric tau protein when pre-phosphorylated by GSK3beta. Using an extracellular vesicle (EVs)-assisted tau neuronal delivery system, we show that exosomal GSK3beta-phosphorylated tau, when added to differentiated SH-SY5Y cells, induced more efficient tau transfer, showing much higher total tau levels and increased tau aggregate formation as compared to wild type exosomal tau. The role of a primary tau phosphorylation site targeted by microtubule-affinity regulating kinases (MARKs), Ser262, was tested by pseudo-phosphorylation using site-directed mutagenesis to aspartate (S262D). S262D tau overexpression significantly enhanced tau release and intracellular tau accumulation, which were concurrent with the increase of pathological states of tau, as determined by immunodetection. Importantly, phosphorylation-induced tau accumulation was augmented by co-transfecting S262D tau with GSK3beta, suggesting a possible interplay between Ser262 phosphorylation and GSK3beta activity in tau pathology. Lastly, we found that pre-treatment of cells with amyloid-beta (Abeta) further tau phosphorylation and accumulation when Ser262 pre-phosphorylation was present, suggesting that S262 may be a primary mediator of Abeta-induced tau toxicity. These findings provide a potential therapeutic target for treating tau-related disorders by targeting specific phospho-tau isoforms and further elucidate the GSK3beta-mediated pathological seeding mechanisms.
36232909	22	30	GSK3beta	Gene	2932
36232909	35	38	Tau	Gene	4137
36232909	39	45	Ser262	ProteinMutation	tmVar:p|Allele|S|262;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	88	91	Tau	Gene	4137
36232909	103	106	Tau	Gene	4137
36232909	179	202	neurofibrillary tangles	Disease	MESH:D055956
36232909	204	208	NFTs	Disease	MESH:D055956
36232909	213	224	tauopathies	Disease	MESH:D024801
36232909	244	247	NFT	Disease	
36232909	305	308	tau	Gene	4137
36232909	362	392	glycogen synthase kinase 3beta	Gene	2932
36232909	394	402	GSK3beta	Gene	2932
36232909	407	410	tau	Gene	4137
36232909	500	503	tau	Gene	4137
36232909	609	617	GSK3beta	Gene	2932
36232909	646	649	tau	Gene	4137
36232909	675	678	tau	Gene	4137
36232909	698	719	SH-SY5Y neuroblastoma	CellLine	CVCL:0019
36232909	822	830	GSK3beta	Gene	2932
36232909	845	848	tau	Gene	4137
36232909	921	924	tau	Gene	4137
36232909	960	968	GSK3beta	Gene	2932
36232909	1016	1019	tau	Gene	4137
36232909	1068	1076	GSK3beta	Gene	2932
36232909	1092	1095	tau	Gene	4137
36232909	1126	1133	SH-SY5Y	CellLine	CVCL:0019
36232909	1164	1167	tau	Gene	4137
36232909	1204	1207	tau	Gene	4137
36232909	1229	1232	tau	Gene	4137
36232909	1287	1290	tau	Gene	4137
36232909	1314	1317	tau	Gene	4137
36232909	1400	1406	Ser262	ProteinMutation	tmVar:p|Allele|S|262;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	1491	1496	S262D	ProteinMutation	tmVar:p|SUB|S|262|D;HGVS:p.S262D;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	1499	1504	S262D	ProteinMutation	tmVar:p|SUB|S|262|D;HGVS:p.S262D;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	1505	1508	tau	Gene	4137
36232909	1547	1550	tau	Gene	4137
36232909	1577	1580	tau	Gene	4137
36232909	1661	1664	tau	Gene	4137
36232909	1737	1740	tau	Gene	4137
36232909	1787	1792	S262D	ProteinMutation	tmVar:p|SUB|S|262|D;HGVS:p.S262D;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	1793	1796	tau	Gene	4137
36232909	1802	1810	GSK3beta	Gene	2932
36232909	1852	1858	Ser262	ProteinMutation	tmVar:p|Allele|S|262;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	1879	1887	GSK3beta	Gene	2932
36232909	1900	1903	tau	Gene	4137
36232909	1965	1977	amyloid-beta	Gene	351
36232909	1979	1984	Abeta	Gene	351
36232909	1994	1997	tau	Gene	4137
36232909	2036	2042	Ser262	ProteinMutation	tmVar:p|Allele|S|262;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	2092	2096	S262	ProteinMutation	tmVar:p|Allele|S|262;VariantGroup:0;CorrespondingGene:4137;CorrespondingSpecies:9606
36232909	2126	2131	Abeta	Gene	351
36232909	2140	2143	tau	Gene	4137
36232909	2144	2152	toxicity	Disease	MESH:D064420
36232909	2221	2242	tau-related disorders	Disease	MESH:C536599
36232909	2273	2276	tau	Gene	4137
36232909	2312	2320	GSK3beta	Gene	2932
36232909	Association	MESH:D064420	CorrespondingGene:4137;CorrespondingSpecies:9606;VariantGroup:0;tmVar:p
36232909	Positive_Correlation	2932	4137
36232909	Association	MESH:C536599	CorrespondingGene:4137;CorrespondingSpecies:9606;VariantGroup:0;tmVar:p
36232909	Association	MESH:D064420	351
36232909	Association	MESH:D055956	4137
36232909	Positive_Correlation	MESH:C536599	4137
36232909	Positive_Correlation	MESH:D064420	4137
36232909	Association	MESH:D024801	4137
36232909	Association	MESH:D064420	4137
36232909	Association	MESH:C536599	4137

